IL6 and congenital rubella syndrome: Due to serious adverse effects induced by CARs, especially cytokine releasing storm (CRS) and neurotoxicity, Actemra (tocilizumab, anti-IL-6 monoclonal antibody) was then approved for CRS, with a further study also showing potential application of Anakinra (an antagonist IL-1 receptor) in such case [244, 245].